Compare FKWL & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | TELA |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 31.4M |
| IPO Year | 1997 | 2019 |
| Metric | FKWL | TELA |
|---|---|---|
| Price | $2.43 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $2.00 |
| AVG Volume (30 Days) | 10.1K | ★ 267.8K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | $46,086,901.00 | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | $7.14 | $14.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.65 | 15.84 |
| 52 Week Low | $2.21 | $0.50 |
| 52 Week High | $5.48 | $1.60 |
| Indicator | FKWL | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 68.34 |
| Support Level | $2.21 | $0.61 |
| Resistance Level | $2.48 | N/A |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 40.00 | 66.60 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.